![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 21, 2015 9:31:10 AM
The Company’s business operations consist of doing business in the cell repair and cell replacement for Equine stock
only at present, but we are pursuing FDA approval for existing and modified products to be used for the repair of the
Human Body. It is estimated that this process will take up to six months assuming a problem-free time-line and funds
available to complete. Its products have been successfully utilised for the repair of horses tendons and have the
added bonus of being patented worldwide, with an exclusive licence in the name of the Company for equine and
human applications. In October 2013 we had to cease trialing the process due to lack of available and sustainable
funds. The new initiative to generate investment into the company will allow us to recommence these trials and move
towards selling the equine product on the open market. As a result, the Company is still in development and approval
stage.
Whilst we have raised the previosly estimated $2million required to obtain US Food and Drug Administration approval
of the patented process for humans and to make the product available to our targeted markets our due diligence has
been successfully completed and contracts now signed subject only to the remittance and clearance of funds. The
new loan investment in the Company will allow trials to recommence. The delay in receiving the new funding, due to
circumstances beyond our control or influence, has prevented us from pursuing the FDA approval, appointing our
preferred investor relations and public relations consultants and commissioning the new website.
http://www.otcmarkets.com/financialReportViewer?symbol=TCEL&id=138904
The Company’s business operations consist of doing business in the cell repair and cell replacement for Equine stock
only at present, but we are pursuing FDA approval for existing and modified products to be used for the repair of the
Human Body. It is estimated that this process will take up to six months assuming a problem-free time-line and funds
available to complete. Its products have been successfully utilised for the repair of horses tendons and have the
added bonus of being patented worldwide, with an exclusive licence in the name of the Company for equine and
human applications. In October 2013 we had to cease trialing the process due to lack of available and sustainable
funds. The new initiative to generate investment into the company will allow us to recommence these trials and move
towards selling the equine product on the open market. As a result, the Company is still in development and approval
stage.
Whilst we have raised the previosly estimated $2million required to obtain US Food and Drug Administration approval
of the patented process for humans and to make the product available to our targeted markets our due diligence has
been completed and we are close to finalising the funding. The new loan investment in the Company would allow
trials to recommence. The delay in receiving the new funding has prevented us from pursuing the FDA approval,
appointing our preferred investor relations and public relations consultants and commissioning the new website.
We have also released into the market substantial amounts of Common stock that had previously been tied up in
convertible loan notes. Further increases in the authorized Common Stocks are not deemed necessary at present.
http://www.otcmarkets.com/financialReportViewer?symbol=TCEL&id=134456
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM